Voyager Therapeutics (NASDAQ:VYGR) Cut to “Hold” at StockNews.com

StockNews.com cut shares of Voyager Therapeutics (NASDAQ:VYGR) from a buy rating to a hold rating in a research note published on Friday morning.

VYGR has been the topic of several other research reports. Canaccord Genuity Group reissued a “buy” rating and set a $14.00 target price on shares of Voyager Therapeutics in a research note on Thursday, November 14th. HC Wainwright reiterated a “buy” rating and set a $30.00 price target on shares of Voyager Therapeutics in a research note on Thursday, November 14th. Citigroup assumed coverage on shares of Voyager Therapeutics in a research note on Monday, December 2nd. They issued a “buy” rating and a $12.00 price objective for the company. Leerink Partners began coverage on shares of Voyager Therapeutics in a research note on Wednesday, October 16th. They set an “outperform” rating and a $15.00 target price on the stock. Finally, Wedbush started coverage on shares of Voyager Therapeutics in a research report on Friday, November 29th. They issued an “outperform” rating and a $11.00 price target for the company. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $17.00.

Voyager Therapeutics Price Performance

Shares of VYGR stock opened at $6.27 on Friday. The company has a 50-day moving average of $6.59 and a two-hundred day moving average of $7.17. The firm has a market cap of $342.53 million, a PE ratio of 8.83 and a beta of 0.90. Voyager Therapeutics has a 1-year low of $5.19 and a 1-year high of $11.72.

Voyager Therapeutics (NASDAQ:VYGR) last posted its earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.29. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. The firm had revenue of $24.63 million during the quarter, compared to the consensus estimate of $12.63 million. During the same quarter last year, the firm earned ($0.59) EPS. Sell-side analysts anticipate that Voyager Therapeutics will post -0.89 EPS for the current fiscal year.

Insider Activity

In other news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the company’s stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $5.82, for a total transaction of $34,914.18. Following the completion of the transaction, the insider now directly owns 86,001 shares of the company’s stock, valued at approximately $500,525.82. This represents a 6.52 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 4.53% of the company’s stock.

Institutional Investors Weigh In On Voyager Therapeutics

Several institutional investors have recently added to or reduced their stakes in VYGR. SG Americas Securities LLC purchased a new stake in Voyager Therapeutics in the second quarter valued at $85,000. SummerHaven Investment Management LLC lifted its holdings in shares of Voyager Therapeutics by 2.5% in the 2nd quarter. SummerHaven Investment Management LLC now owns 77,293 shares of the company’s stock valued at $611,000 after purchasing an additional 1,921 shares during the last quarter. Bank of New York Mellon Corp increased its position in Voyager Therapeutics by 17.7% during the second quarter. Bank of New York Mellon Corp now owns 294,420 shares of the company’s stock worth $2,329,000 after buying an additional 44,289 shares during the period. Patriot Financial Group Insurance Agency LLC purchased a new stake in Voyager Therapeutics in the second quarter valued at approximately $1,012,000. Finally, Commonwealth Equity Services LLC boosted its holdings in shares of Voyager Therapeutics by 36.8% in the second quarter. Commonwealth Equity Services LLC now owns 77,905 shares of the company’s stock valued at $616,000 after acquiring an additional 20,950 shares during the period. Hedge funds and other institutional investors own 48.03% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.